EIF4E and lung carcinoma: N-7 benzyl guanosine monophosphate tryptamine phosphoramidate prodrug (4Ei-1) prevents eIF4E cap binding and triggers proteasomal degradation of eIF4E, thereby chemosensitizing breast and lung cancer to gemcitabine [198].